Confusion about diffusion and the art of misinterpreting data when comparing different botulinum toxins used in aesthetic applications

References

• De Almeida A. T., de Boulle K. Diffusion characteristics of botulinum neurotoxin products and their clinical significance in cosmetic applications. J Cosmet Laser Ther 2007; 9((suppl 1))17–22
   PubMedGoogle Scholar
• Aoki R., Francis J., Reynolds H., Leumer D. Comparison of the therapeutic windows of different neurotoxin preparations in an animal model. Neurol 2003; 60((5, suppl 1))A212–13
   Google Scholar
• Francis J., Satorius A. L., Ardila M. C., Brown M. S., Nicholson G. S., Aoki K. R. Pharmacological evaluation of BOTOX®, Dysport® and Myobloc® in pre‐clinical models of efficacy and safety., Presented at the 10th Congress of the European Federation of Neurological Societies (EFNS 2006). September 2006; poster P1169
   Google Scholar
• Aoki K. R., Ranoux D., Wissel J. Using translational medicine to understand clinical differences between botulinum toxin formulations. Eur J Neurol 2006; 13((suppl 4))10–19
   PubMedGoogle Scholar
• BOTOX® summary of product characteristics, Allergan Ltd, UK; 7 June 2007
   Google Scholar
• Pickett A. M., Hambleton P. Dose standardisation of botulinum toxin. Lancet 1994; 344: 474–5
   PubMed Web of Science ®Google Scholar
• Hambleton P., Pickett A. M. Potency equivalence of botulinum toxin preparations. J R Soc Med 1994; 87: 719
   PubMed Web of Science ®Google Scholar
• Pearce L. B., Borodic G. E., First E. R., MacCallum R. D. Measurement of botulinum toxin activity: Evaluation of the lethality assay. Toxicol Appl Pharmacol 1994; 128: 69–77
   PubMed Web of Science ®Google Scholar
• Aoki K. R. A comparison of the safety margins of botulinum neurotoxin serotypes A, B and F in mice. Toxicon 2001; 39: 1815–20
   PubMed Web of Science ®Google Scholar
• Aoki K. R., Satorius A., Ardila C., Brown M., Nicholson G., Francis J. Pharmacology of BOTOX®, Dysport® and Myobloc® and BoNT/A in animal models of safety and efficacy. Neurotox Res 2006; 9: 236
   Google Scholar
• Pickett A., O’Keeffe R., Panjwani N. The protein load of therapeutic botulinum toxins. Eur J Neurol 2007; 14: e11
   Google Scholar
• Rosales R. L., Bigalke H., Dressler D. Pharmacology of botulinum toxin: Differences between Type A preparations. Eur J Neurol 2006; 13((suppl 1))2–10
   PubMed Web of Science ®Google Scholar
• BOTOX® prescribing information, Allergan Inc, USA; October 2006
   Google Scholar
• De Almeida A. R. T., Marques E., de Almeida J., Cunha T., Boraso R. Pilot study comparing the diffusion of two formulations of botulinum toxin Type A in patients with forehead hyperhidrosis. Dermatol Surg 2007; 33: S37–43
   Google Scholar
• Bihari K. Safety, effectiveness, and duration of effect of BOTOX® compared with Dysport® for blepharospasm, cervical dystonia, and hemifacial spasm., Presented at the 7th Congress of the European Federation of Neurological Societies. Helsinki, Finland; August 30 – September 2, 2003
   Google Scholar
• Karsai S., Adrian R., Hammes S., Thimm J., Raulin C. A randomized double‐blind study of the effect of botox and dysport/reloxin on forehead wrinkles and electromyographic activity. Arch Dermatol 2007; 143: 1447–9
   PubMed Web of Science ®Google Scholar
• Hexsel D., Dal’Forno T., Hexsel C., do Prado D. Z. A randomized pilot study comparing the action halos of two commercial preparations of botulinum toxin Type A. Dermatol Surg 2007; 34: 1–8
   PubMed Web of Science ®Google Scholar
• Hexsel D., Dal T., do Prado D. Z., Hexsel C. Diffusion, dispersion, or action halos of botulinum toxins? A pilot study comparing two commercial preparations of Type A botulinum toxins. J Am Acad Dermatol 2005; 52((3, suppl 2))AB2
   Google Scholar
• Friday D., Bigalke H., Frevert J. In vitro stability of botulinum toxin complex preparations at physiological pH and temperature. Naunyn Schmiedebergs Arch Pharmacol 2002; 365((suppl 2))R20
   Google Scholar
• Frevert J., Rummel A., Bigalke H. Stability of BoNT/A complex at physiological conditions., Presented at the 44th Meeting of the Interagency Botulism Coordinating Committee. California, 2007; Poster SF‐4
   Google Scholar
• Wagman J., Bateman J. B. Botulinum Type A toxin: Properties of a toxic dissociation product. Arch Biochem Biophys 1953; 45: 375–83
   PubMed Web of Science ®Google Scholar
• Dodd S. L., Rowell B. A., Vrabas I. S., Arrowsmith R. J., Weatherill P. J. A comparison of the spread of three formulations of botulinum neurotoxin A as determined by effects on muscle function. Eur J Neurol 1998; 5: 181–6
   Web of Science ®Google Scholar
• Tang‐Liu D. D‐S., Aoki K. R., Dolly J. O., de Paiva A., Houchen T. L., Chasseaud L. F., et al. Intramuscular injection of 125I‐botulinum neurotoxin‐complex versus 125I‐botulinum‐free neurotoxin: Time course of tissue distribution. Toxicon 2004; 42: 461–9
   Google Scholar
• Lowe P., Patnaik R., Lowe N. J. A comparison of two botulinum Type A toxin preparations for the treatment of glabellar lines: Double‐blind, randomized, pilot study. Dermatol Surg 2005; 31: 1651–4
   Google Scholar
• Lowe P., Patnaik R., Lowe N. Comparison of two formulations of botulinum toxin Type A for the treatment of glabellar lines: A double‐blind, randomized study. J Am Acad Dermatol 2006; 55: 976–82
   Google Scholar
• Rzany B., Nast A. Head‐to‐head studies of botulinum toxin A in aesthetic medicine: Which evidence is good enough? (Letter). J Am Acad Dermatol 2007; 56: 1066–7
   PubMed Web of Science ®Google Scholar
• De Maio M., Rzany B. Botulinum toxin in aesthetic medicine. Springer, Heidelberg 2007
   Google Scholar